Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma (NASDAQ: NVCT) has successfully completed a drug-drug interaction (DDI) study for NXP900 in healthy volunteers. The study revealed that NXP900 is classified as a weak inhibitor of CYP3A, supporting its potential combination with EGFR and ALK inhibitors in non-small cell lung cancer (NSCLC) treatment.
The study involved 14 healthy volunteers and showed NXP900 increased Midazolam concentration by less than 2-fold. No serious adverse events were reported, with only mild to moderate diarrhea and non-infection related white blood cell count increases observed.
The company is completing its Phase 1a dose escalation study and plans to advance to Phase 1b testing, which will evaluate NXP900 both as a single agent and in combinations with leading EGFR and ALK drugs in patients whose cancers may be sensitive to SRC/YES1 inhibition.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, the company's Chairman and CEO, will deliver a presentation on May 20th, 2025, from 10:30 to 11:00 a.m. ET. The presentation will be accessible via webcast for interested investors and stakeholders.
Nuvectis Pharma presented key findings for their cancer drug NXP900 at the 2025 AACR Meeting. The Phase 1a dose-escalation study, involving 29 patients with advanced cancers, demonstrated promising results with doses up to 250 mg/day showing an acceptable safety profile.
Key highlights:
- Treatment achieved robust pharmacodynamic responses at tolerated doses
- SRC inhibition exceeded 90% after a single dose
- Most side effects were Grade 1-2, including fatigue and nausea
- Median patient age was 62 years, with 62% males
Three preclinical posters revealed NXP900's potential in NSCLC (non-small cell lung cancer), both as a single agent and in combination with existing therapies. The company plans to commence Phase 1b trials targeting patients with YES1 gene amplifications and hippo pathway alterations, as well as exploring combinations with market-leading therapies for resistant NSCLC.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced upcoming presentations for their product NXP900 at the 2025 American Association for Cancer Research Meeting (AACR). The conference will be held from April 25th to April 30th in Chicago, IL. The company focuses on developing innovative treatments for serious unmet medical needs in cancer treatment.
Nuvectis Pharma (NVCT), a biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 37th Annual Roth Conference. The event will take place from March 17th-19th in Dana Point, California, where Ron Bentsur, Chairman and Chief Executive Officer, will engage in a fireside chat discussion.
The conference participation highlights Nuvectis's continued engagement with the investment community and its focus on developing innovative treatments for serious unmet medical needs in cancer therapy.
Nuvectis Pharma (NASDAQ: NVCT) has announced new research findings from the Cleveland Clinic demonstrating enhanced efficacy when combining their drug NXP900 with osimertinib (Tagrisso®) in treating EGFR-mutated non-small cell lung cancer (NSCLC).
The study, published in Molecular Cancer Research (2025), showed that the combination therapy was superior to osimertinib alone in vivo, resulting in decreased cell proliferation and increased apoptosis in vitro. This research validates previous findings from AstraZeneca showing NXP900's ability to reverse osimertinib resistance in resistant cell lines.
The company is approaching completion of its Phase 1a dose escalation study for NXP900 and plans to initiate a Phase 1b program, exploring opportunities both as a standalone treatment and in combination with existing anti-cancer medications.
Nuvectis Pharma (NASDAQ: NVCT) reported its 2024 financial results and business highlights, showing progress in its clinical-stage oncology drug candidates. The company's NXP800 received Orphan Drug Designation from the FDA for ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. A Phase 1b study in platinum-resistant, ARID1a-mutated ovarian cancer continues with updated results expected in Q2 2025.
For NXP900, the Phase 1a dose escalation study is ongoing with preparations underway for Phase 1b trials starting mid-2025. The upcoming program will evaluate NXP900 as monotherapy in YES1/SRC-driven solid tumors and in combination with EGFR and ALK inhibitors for non-small cell lung cancer.
Financially, Nuvectis completed a follow-on offering in February 2025, raising $15.5 million in gross proceeds, extending cash runway into 2027. The company reported a net loss of $19.0 million for 2024, compared to $22.3 million in 2023, a $3.3 million improvement. Cash and equivalents stood at $18.5 million as of December 31, 2024, slightly down from $19.1 million at the end of 2023.
Nuvectis Pharma (NVCT) has successfully closed its previously announced public offering, raising $15.5 million in gross proceeds. The offering consisted of 2,700,000 shares of common stock at $5.00 per share, along with the full exercise of the underwriter's over-allotment option for an additional 405,000 shares.
Lucid Capital Markets served as the sole book runner for the offering. The company plans to use the net proceeds to advance the development programs of NXP800 and NXP900, hire additional personnel, fund capital expenditures, cover public company operating costs, and other general corporate purposes. The offering was conducted under Nuvectis's shelf registration statement on Form S-3.
Nuvectis Pharma (NASDAQ: NVCT) has announced the pricing of its public offering of 2,700,000 shares of common stock at $5.00 per share, expecting to raise gross proceeds of $13.5 million. The company has granted the underwriter a 30-day option to purchase up to 405,000 additional shares at the same price.
The offering is expected to close on February 6, 2025, with Lucid Capital Markets acting as the sole book runner. The proceeds will be used to advance development programs of NXP800 and NXP900, hire additional personnel, cover capital expenditures, operating costs as a public company, and other general corporate purposes.
The offering is being made pursuant to Nuvectis's shelf registration statement on Form S-3, which was declared effective by the SEC on March 29, 2023.